Acquisition of INBRIJA (levodopa inhalation powder) and (F)AMPYRA (fampridine) expands specialty neurology portfolio Lays groundwork for Parkinson’s disease franchise and anchor in multiple sclerosis ...

inbrija-1 Inbrija (levodopa inhalation powder; Acorda Therapeutics) is the first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease ...

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in ...

Extension study showed that levodopa inhalation powder maintained its efficacy in achieving an ON state in patients with Parkinson disease experiencing OFF periods. PHILADELPHIA — Levodopa inhalation ...

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a ...

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present new data on INBRIJA® (levodopa inhalation powder) and OFF Periods at the upcoming 3rd Pan ...

Self-administered levodopa inhalation powder (Inbrija, Acorda) can significantly improve motor function during "off" periods in patients with Parkinson's disease (PD), results from a phase 3 trial ...

Inbrija (previously known as CVT-301) is a self-administered, orally inhaled levodopa; it is designed to deliver a precise dose of a dry powder formulation of L-dopa to the lung. The Food and Drug ...

Acorda Therapeutics has suffered its second setback this week, acknowledging that the FDA has extended by three months the PDUFA target decision date for its NDA of its Parkinson’s disease ...

Investors and others in the field of Parkinson's disease (PD) are weighing the odds of two major players in treating "off" episodes: Sunovion Pharmaceuticals Inc. with apomorphine sublingual film (APL ...

Parkinson’s affects about one million people in the U.S. and millions more globally. Medicines have existed to help with Parkinson’s symptoms for many years, but many people with Parkinson’s, about 40 ...